The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Urinary Incontinence

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Urinary Incontinence


Psychiatry related information on Urinary Incontinence


High impact information on Urinary Incontinence


Chemical compound and disease context of Urinary Incontinence


Biological context of Urinary Incontinence


Anatomical context of Urinary Incontinence


Gene context of Urinary Incontinence


Analytical, diagnostic and therapeutic context of Urinary Incontinence


  1. Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients. Ruud Bosch, J.L., Groen, J. Lancet (1996) [Pubmed]
  2. Frequency analysis and clinical characterization of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Korean patients. Lee, W.Y., Jin, D.K., Oh, M.R., Lee, J.E., Song, S.M., Lee, E.A., Kim, G.M., Chung, J.S., Lee, K.H. Arch. Neurol. (2003) [Pubmed]
  3. Frontal lobe meningioma and depression. Lahmeyer, H.W. The Journal of clinical psychiatry. (1982) [Pubmed]
  4. Stress induced urinary incontinence in patients with spinocerebellar degeneration. Sakakibara, R., Hattori, T., Kita, K., Arai, K., Yamanishi, T., Yasuda, K. J. Neurol. Neurosurg. Psychiatr. (1998) [Pubmed]
  5. Long-term efficacy of periurethral collagen injection for the treatment of urinary incontinence secondary to myelomeningocele. Block, C.A., Cooper, C.S., Hawtrey, C.E. J. Urol. (2003) [Pubmed]
  6. A pharmacological paradigm for urinary incontinence and enuresis. Ambrosini, P.J. Journal of clinical psychopharmacology. (1984) [Pubmed]
  7. Broadening a classic clinical triad: The hypokinetic motor disorder of normal pressure hydrocephalus also affects the hand. Nowak, D.A., Topka, H.R. Exp. Neurol. (2006) [Pubmed]
  8. Pharmacologic treatment for detrusor overactivity. Lai, H.H., Boone, T.B., Appell, R.A. Current urology reports. (2002) [Pubmed]
  9. Hypertension in the elderly. Maddens, M., Imam, K., Ashkar, A. Prim. Care (2005) [Pubmed]
  10. ANA endorses guidelines for smoking cessation, urinary incontinence. Canavan, K. The American nurse. (1996) [Pubmed]
  11. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Cockayne, D.A., Hamilton, S.G., Zhu, Q.M., Dunn, P.M., Zhong, Y., Novakovic, S., Malmberg, A.B., Cain, G., Berson, A., Kassotakis, L., Hedley, L., Lachnit, W.G., Burnstock, G., McMahon, S.B., Ford, A.P. Nature (2000) [Pubmed]
  12. Migration and granulomatous reaction after periurethral injection of polytef (Teflon). Malizia, A.A., Reiman, H.M., Myers, R.P., Sande, J.R., Barham, S.S., Benson, R.C., Dewanjee, M.K., Utz, W.J. JAMA (1984) [Pubmed]
  13. Urinary incontinence associated with metoclopramide. Kumar, B.B. JAMA (1984) [Pubmed]
  14. Medical management of urinary incontinence. Diokno, A.C. Gastroenterology (2004) [Pubmed]
  15. Urinary incontinence: an unrecognised adverse effect with donepezil. Hashimoto, M., Imamura, T., Tanimukai, S., Kazui, H., Mori, E. Lancet (2000) [Pubmed]
  16. Emepronium bromide in urinary incontinence. Berglund, F., Glenne, P.O. Lancet (1977) [Pubmed]
  17. Flunarizine: a once-daily therapy for urinary incontinence. Palmer, J.H., Worth, P.H., Exton-Smith, A.N. Lancet (1981) [Pubmed]
  18. Therapeutic opportunities from muscarinic receptor research. Eglen, R.M., Choppin, A., Watson, N. Trends Pharmacol. Sci. (2001) [Pubmed]
  19. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Gupta, S.K., Sathyan, G., Lindemulder, E.A., Ho, P.L., Sheiner, L.B., Aarons, L. Clin. Pharmacol. Ther. (1999) [Pubmed]
  20. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Skinner, M.H., Kuan, H.Y., Pan, A., Sathirakul, K., Knadler, M.P., Gonzales, C.R., Yeo, K.P., Reddy, S., Lim, M., Ayan-Oshodi, M., Wise, S.D. Clin. Pharmacol. Ther. (2003) [Pubmed]
  21. Metabolic alterations in the hypothalamus and basal forebrain in vascular dementia. Ishunina, T.A., Kamphorst, W., Swaab, D.F. J. Neuropathol. Exp. Neurol. (2004) [Pubmed]
  22. Urodynamic properties and neurotransmitter dependence of urinary bladder contractility in the BK channel deletion model of overactive bladder. Thorneloe, K.S., Meredith, A.L., Knorn, A.M., Aldrich, R.W., Nelson, M.T. Am. J. Physiol. Renal Physiol. (2005) [Pubmed]
  23. Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials. Jones, S.E., Shuba, L.M., Zhabyeyev, P., McCullough, J.R., McDonald, T.F. Br. J. Pharmacol. (2000) [Pubmed]
  24. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion. Oki, T., Toma-Okura, A., Yamada, S. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  25. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Altan-Yaycioglu, R., Yaycioglu, O., Aydin Akova, Y., Guvel, S., Ozkardes, H. British journal of clinical pharmacology. (2005) [Pubmed]
  26. Intravesical capsaicin for treatment of detrusor hyperreflexia. Fowler, C.J., Beck, R.O., Gerrard, S., Betts, C.D., Fowler, C.G. J. Neurol. Neurosurg. Psychiatr. (1994) [Pubmed]
  27. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Dessole, S., Rubattu, G., Ambrosini, G., Gallo, O., Capobianco, G., Cherchi, P.L., Marci, R., Cosmi, E. Menopause (New York, N.Y.) (2004) [Pubmed]
  28. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. Ghoniem, G.M., Van Leeuwen, J.S., Elser, D.M., Freeman, R.M., Zhao, Y.D., Yalcin, I., Bump, R.C. J. Urol. (2005) [Pubmed]
  29. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Garely, A.D., Burrows, L. Drug safety : an international journal of medical toxicology and drug experience. (2004) [Pubmed]
  30. Urethral pressure profiles before and after Ornade administration in patients with stress urinary incontinence. Montague, D.K., Stewart, B.H. J. Urol. (1979) [Pubmed]
  31. Selective muscarinic antagonists. II. Synthesis and antimuscarinic properties of biphenylylcarbamate derivatives. Naito, R., Takeuchi, M., Morihira, K., Hayakawa, M., Ikeda, K., Shibanuma, T., Isomura, Y. Chem. Pharm. Bull. (1998) [Pubmed]
  32. The role of estrogen receptor, progesterone receptor and p53 in development of stress urinary incontinence. Bai, S.W., Jung, Y.W., Kwon, H.S., Yoon, J.M., Shin, J.S., Kim, S.K., Park, K.H., Park, J.H. Yonsei Med. J. (2004) [Pubmed]
  33. A review of the L-arginine - nitric oxide - guanylate cyclase pathway as a mediator of lower urinary tract physiology and symptoms. Stothers, L., Laher, I., Christ, G.T. The Canadian journal of urology. (2003) [Pubmed]
  34. Overactive bladder and incontinence in the absence of the BK large conductance Ca2+-activated K+ channel. Meredith, A.L., Thorneloe, K.S., Werner, M.E., Nelson, M.T., Aldrich, R.W. J. Biol. Chem. (2004) [Pubmed]
  35. Cool (TRPM8) and hot (TRPV1) receptors in the bladder and male genital tract. Stein, R.J., Santos, S., Nagatomi, J., Hayashi, Y., Minnery, B.S., Xavier, M., Patel, A.S., Nelson, J.B., Futrell, W.J., Yoshimura, N., Chancellor, M.B., De Miguel, F. J. Urol. (2004) [Pubmed]
  36. Hypoplastic dysplastic kidney with a vaginal ectopic ureter identified by technetium-99m-DMSA scintigraphy. Bozorgi, F., Connolly, L.P., Bauer, S.B., Neish, A.S., Tan, P.E., Schofield, D., Treves, S.T. J. Nucl. Med. (1998) [Pubmed]
  37. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. Oki, T., Kimura, R., Saito, M., Miyagawa, I., Yamada, S. J. Urol. (2004) [Pubmed]
  38. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Lee, K.S., Choo, M.S., Kim, D.Y., Kim, J.C., Kim, H.J., Min, K.S., Lee, J.B., Jeong, H.J., Lee, T., Park, W.H. J. Urol. (2005) [Pubmed]
  39. New periurethral bulking agent for stress urinary incontinence: modified technique and early results. Madjar, S., Covington-Nichols, C., Secrest, C.L. J. Urol. (2003) [Pubmed]
  40. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. Davila, G.W., Daugherty, C.A., Sanders, S.W. J. Urol. (2001) [Pubmed]
WikiGenes - Universities